Advertisement
The Essential Resource for the Medical Design Engineering Community
Subscribe to MDT Magazine All

Duro Extend Capsules for Men: Recall - Undeclared Drug Ingredient

November 5, 2010 9:30 am | by U.S. Food & Drug Administration | News | Comments

Product marketed as dietary supplement contains undeclared Sulfoaidenafil, which may interact with nitrates found in some prescription drugs and lower blood pressure to dangerous levels.

TOPICS:

Sun Healthcare says restructuring approved

November 5, 2010 8:45 am | by The Associated Press | News | Comments

Health care facility operator Sun Healthcare Group Inc. said Friday shareholders have approved its restructuring plan, which will separate Sun into two publicly traded companies.The company will split into Sun Healthcare Group Inc., which will operate skilled nursing centers and assisted living...

Infants' hemodynamic responses to happy and angry facial expressions

November 5, 2010 7:41 am | by EurekAlert | News | Comments

(National Institute for Physiological Sciences) Japanese research group led by Prof. Ryusuke Kakigi and Dr. Emi Nakato, National Institute for Physiological Sciences, and Prof. Masami K. Yamaguchi, Chuo University, found that the hemispheric differences in the temporal area...

TOPICS:
Advertisement

Xeomin® (incobotulinumtoxinA) Data To Be Presented At The 71st Annual Assembly Of The American Academy Of Physical Medicine And Rehabilitation

November 5, 2010 7:39 am | by Bio-Medicine.Org | News | Comments

GREENSBORO, N.C., Nov. 5, 2010 /- Merz Pharmaceuticals announced today that data from stability and clinical studies evaluating Xeomin® (incobotulinumtoxinA), a botulinum toxin type A free from accessory proteins, will be presented at the 71st Annual Assembly of the American Academy...

TOPICS:

Dehaier Medical Wins $2 Million Distribution Bid for Rural Healthcare Construction Project

November 5, 2010 7:39 am | by Bio-Medicine.Org | News | Comments

BEIJING, Nov. 5, 2010 /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems Ltd. (Nasdaq: DHRM ) ("Dehaier" or the "Company"), an emerging leader in the development, assembly, marketing and sale of medical devices and homecare medical products in China, today announced that it has won a...

TOPICS:

SAFE IN COMMON Launches Global Injection Safety Website

November 5, 2010 7:39 am | by Bio-Medicine.Org | News | Comments

LEWISBERRY, Pa., Nov. 5, 2010 /- SAFE IN COMMON, an online community of  healthcare workers, educators, patients, community leaders and individuals, today announced the launch of its website dedicated to raising awareness of global injection safety challenges. SAFE IN COMMON's launch...

TOPICS:

IntegenX Launches the Apollo 324 System for Automated DNA Library Preparation at the ASHG Meeting

November 5, 2010 7:39 am | by Bio-Medicine.Org | News | Comments

PLEASANTON, Calif., Nov. 5, 2010 /- IntegenX, Inc. (IXI) today at the 60th Annual American Society of Human Genetics Meeting announced the launch of their Apollo 324™ System, a benchtop robotic workstation that automates the construction of DNA fragment libraries for next-generation...

TOPICS:

Varian Medical Systems Management to Present at Lazard Capital Markets 7th Annual Healthcare Conference

November 5, 2010 7:38 am | by Bio-Medicine.Org | News | Comments

PALO ALTO, Calif., Nov. 5, 2010 /- Varian Medical Systems (NYSE: VAR ) is scheduled to present at Lazard Capital Markets Healthcare Conference at 9:30 a.m. ET on Wednesday, November 17th at the St. Regis Hotel in New York City. Participating executives will include Elisha Finney, senior...

TOPICS:
Advertisement

EnVivo Pharmaceuticals Research Shows EVP-6124 Acts as Acetylcholine Co-Agonist

November 5, 2010 7:38 am | by Bio-Medicine.Org | News | Comments

WATERTOWN, Mass., Nov. 5, 2010 /- EnVivo Pharmaceuticals today announced it has discovered that EVP-6124, its alpha-7 nicotinic acetylcholine receptor agonist, possesses a novel mechanism not previously seen in the scientific community: it acts as a co-agonist with Acetylcholine (ACh) to...

TOPICS:

Masimo to Present at Lazard Capital Markets 7th Annual Healthcare Conference

November 5, 2010 7:36 am | by Bio-Medicine.Org | News | Comments

IRVINE, Calif., Nov. 5, 2010 /- Masimo (Nasdaq: MASI ) today announced that its management is scheduled to present at the Lazard Capital Markets 7th Annual Healthcare Conference at The St. Regis Hotel in New York on Tuesday, November 16, at 8:55 a.m. ET.  A live audiocast of the...

TOPICS:

Daktari Diagnostics raises $1.8M financing

November 5, 2010 7:36 am | by Mass High Tech: The Journal of New England Technology | News | Comments

Global health firm Daktari Diagnostics Inc., which focuses on delivering diagnostic test results to doctors and patients, has landed $1.8 million in equity financing, according to a filing with the U.S. Securities and Exchange Commission.

TOPICS:

Sequenom to Present at Two Financial Conferences in November

November 5, 2010 7:35 am | by Bio-Medicine.Org | News | Comments

SAN DIEGO, Nov. 5, 2010 /- Sequenom, Inc. (Nasdaq: SQNM ) today announced that company management will present an overview of the company at the following conferences in November. (Logo:   http://photos.prnewswire.com/prnh/20040415/SQNMLOGO ) (Logo:  ...

TOPICS:

United American Healthcare Corporation Announces Senior Management Appointments and Relocation to Chicago

November 5, 2010 5:32 am | by Bio-Medicine.Org | News | Comments

DETROIT, Nov. 5, 2010 /- United American Healthcare Corporation (OTCQB: UAHC) today announced that its Board of Directors has approved key appointments to the Company's senior management team.  UAHC management also announced that the Company will relocate its headquarters from...

TOPICS:

Pervasis Therapeutics Awarded Four Grants Under the Qualifying Therapeutic Discovery Project

November 5, 2010 4:34 am | by Bio-Medicine.Org | News | Comments

CAMBRIDGE, Mass., Nov. 5, 2010 /- Pervasis Therapeutics, Inc. today announced that it has been awarded over $920,000 in grants through the U.S. government's Qualifying Therapeutic Discovery Project, which provides tax credits and grants to projects that show significant potential to...

TOPICS:

FDA Approves Cymbalta® for the Management of Chronic Musculoskeletal Pain

November 4, 2010 8:35 pm | by Bio-Medicine.Org | News | Comments

INDIANAPOLIS, Nov. 4, 2010 /- Eli Lilly and Company (NYSE: LLY ) announced that the U.S. Food and Drug Administration (FDA) has approved Cymbalta® (duloxetine HCl) for the management of chronic musculoskeletal pain. This has been established in studies in patients with chronic low...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading